Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | JUL 28 | CA/CAplus patent coverage enhanced |
| NEWS 3 | JUL 28 | EPFULL enhanced with additional legal status information from the epoline Register |
| NEWS 4 | JUL 28 | IFICDB, IFIPAT, and IFIUDB reloaded with enhancements |
| NEWS 5 | JUL 28 | STN Viewer performance improved |
| NEWS 6 | AUG 01 | INPADOCDB and INPAFAMDB coverage enhanced |
| NEWS 7 | AUG 13 | CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998 |
| NEWS 8 | AUG 15 | CAOLD to be discontinued on December 31, 2008 |
| NEWS 9 | AUG 15 | CAplus currency for Korean patents enhanced |
| NEWS 10 | AUG 27 | CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information |
| NEWS 11 | SEP 18 | Support for STN Express, Versions 6.01 and earlier, to be discontinued |
| NEWS 12 | SEP 25 | CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances |
| NEWS 13 | SEP 26 | WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced |
| NEWS 14 | SEP 29 | IFICLS enhanced with new super search field |
| NEWS 15 | SEP 29 | EMBASE and EMBAL enhanced with new search and display fields |
| NEWS 16 | SEP 30 | CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents |
| NEWS 17 | OCT 07 | EPFULL enhanced with full implementation of EPC2000 |
| NEWS 18 | OCT 07 | Multiple databases enhanced for more flexible patent number searching |
| NEWS 19 | OCT 22 | Current-awareness alert (SDI) setup and editing enhanced |
| NEWS 20 | OCT 22 | WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications |
| NEWS 21 | OCT 24 | CHEMLIST enhanced with intermediate list of pre-registered REACH substances |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

| | |
|---|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:58:18 ON 17 NOV 2008

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 17:58:31 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-538196genA.str





chain nodes :
2 15 16 20
ring nodes :
1 3 4 5 6 7 8 12 13
chain bonds :
1-2 2-5 13-16 13-20 15-16
ring bonds :
1-12 1-13 3-4 3-8 4-5 5-6 6-7 7-8 12-13
exact/norm bonds :
1-12 1-13 2-5 3-4 3-8 4-5 5-6 6-7 7-8 12-13 13-20 15-16
exact bonds :
1-2 13-16

G1:Cb,Cy,Hy,Ak

G2:C,S,N,Cb,Cy,Hy

G3:Cb,Cy,Hy,Ak

Match level :
1:Atom 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 12:Atom 13:Atom
15:CLASS 16:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 Cb,Cy,Hy,Ak

G2 C,S,N,Cb,Cy,Hy

G3 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 17:59:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1885257 TO ITERATE

51.4% PROCESSED 968672 ITERATIONS 217 ANSWERS

53.0% PROCESSED 1000000 ITERATIONS 217 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.23

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1885257 TO 1885257
PROJECTED ANSWERS: 349 TO 469

L2 217 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 179.28 179.49

FILE 'CAPLUS' ENTERED AT 18:00:12 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008  (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3           8 L2

=> d l3 1-8 abs ibib hitstr

L3   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2008 ACS on STN
AB   There is considerable interest in developing KOP Opioid receptor ligands as clin. useful analgesics. Moreover, compds. with mixed KOP receptor and mu-opioid peptide (MOP) receptor agonist/antagonist properties could have a better therapeutic potential. The benzomorphan-based synthetic ligands MPCB and CCB have been shown to bind KOP receptors with high affinity and selectivity. We report here a series of compds. synthesized to perform structure-affinity relationship (SAR) studies on MPCB. The aim of this study was to optimize KOP receptor-ligand interaction and to modulate MOP receptor selectivity. In the benzylamide analog of MPCB (compound 9) the presence of a third aromatic nucleus, at an appropriate distance and conformation with respect to aromatic pharmacophoric residues, increased KOP receptor affinity by about 6-fold compared to MPCB (Ki = 35 nM and Ki = 240 nM, resp.). Instead, compound 28 with a tertiary amino group in the nitrogen substituent displayed a comparable KOP receptor affinity (Ki = 179 nM) but also high MOP receptor affinity (Ki = 45 nM). Thus, the present study shows that in benzomorphan-based ligands the presence of different functional groups in the nitrogen substituent, ranging from a pos. charged amine to an addnl. aromatic ring, is able to promote the correct aligment of aromatic pharmacophoric residues with MOP and KOP receptor types. Evaluation of docking simulations of compds. 9 and 28 into the KOP and MOP receptor displayed selective ligand interactions with the important amino acid residues Tyr320 (TMVII) and Trp318 (TMVII), resp.
ACCESSION NUMBER:  2007:1311715  CAPLUS
DOCUMENT NUMBER:  148:112285
TITLE:  New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands
AUTHOR(S):  Pasquinucci, L.; Iadanza, M.; Marrazzo, A.; Prezzavento, O.; Ronsisvalle, S.; Scoto, G. M.; Parenti, C.; De Luca, L.; Ronsisvalle, G.
CORPORATE SOURCE:  Department of Pharmaceutical Sciences, University of Catania, Italy
SOURCE:  Pharmazie (2007), 62(11), 813-824
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER:  Govi-Verlag Pharmazeutischer Verlag GmbH
DOCUMENT TYPE:  Journal
LANGUAGE:  English
IT   1001017-64-6P 1001017-66-8P 1001017-68-0P
     1001017-69-1P 1001017-70-4P 1001017-72-6P
     1001017-74-8P 1001017-76-0P 1001017-78-2P
     1001017-80-6P 1001017-82-8P 1001017-86-2P
     1001017-88-4P 1001017-90-8P 1001017-92-0P
     1001017-94-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(New benzomorphan derivs. of MPCB as MOP and KOP receptor ligands)

RN 1001017-64-6 CAPLUS

CN Cyclopropanecarboxamide, 1-phenyl-N-[(1R)-1-phenylethyl]-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-63-5
CMF C33 H38 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 1001017-66-8 CAPLUS

CN Cyclopropanecarboxamide, 1-phenyl-N-(phenylmethyl)-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-65-7
CMF C32 H36 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 1001017-68-0 CAPLUS
CN Cyclopropanecarboxamide, N,N-diethyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-67-9
CMF C29 H38 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 1001017-69-1 CAPLUS
CN Cyclopropanecarboxamide, N-methyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1001017-70-4 CAPLUS
CN Cyclopropanecarboxamide, N-ethyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 1001017-72-6 CAPLUS
CN Cyclopropanecarboxamide, 1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-71-5
CMF C25 H30 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 1001017-74-8 CAPLUS
CN Cyclopropanecarboxamide, N,N-dimethyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-73-7

CMF C27 H34 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 1001017-76-0 CAPLUS
CN Cyclopropanecarboxamide, N,1-diphenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-75-9
CMF C31 H34 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 1001017-78-2 CAPLUS
CN Methanone, [(1S,2R)-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]cyclopropyl]-1-pyrrolidinyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-77-1
CMF C29 H36 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 1001017-80-6 CAPLUS
CN Methanone, [(1S,2R)-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]cyclopropyl]-1-piperidinyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-79-3
CMF C30 H38 N2 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-82-8 CAPLUS
CN Methanone, 4-morpholinyl[(1S,2R)-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]cyclopropyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-81-7
CMF C29 H36 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 1001017-86-2 CAPLUS
CN 2,6-Methano-3-benzazocin-8-ol, 3-[[(1R,2S)-2-[(acetyloxy)methyl]-2-phenylcyclopropyl]methyl]-1,2,3,4,5,6-hexahydro-6,11-dimethyl-, (2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-85-1
CMF C27 H33 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 1001017-88-4 CAPLUS
CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-[[(1R,2S)-2-(hydroxymethyl)-2-phenylcyclopropyl]methyl]-6,11-dimethyl-, (2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-87-3
CMF C25 H31 N O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 1001017-90-8 CAPLUS
CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-[[(1R,2S)-2-phenyl-2-(1-pyrrolidinylmethyl)cyclopropyl]methyl]-,

(2R,6R,11R)-, ethanedioate (1:1)  (CA INDEX NAME)

CM  1

CRN  1001017-89-5
CMF  C29 H38 N2 O

Absolute stereochemistry.  Rotation (-).




CM  2

CRN  144-62-7
CMF  C2 H2 O4




RN  1001017-92-0  CAPLUS
CN  2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-[[(1R,2S)-2-phenyl-2-(1-piperidinylmethyl)cyclopropyl]methyl]-, (2R,6R,11R)-, ethanedioate (1:1)  (CA INDEX NAME)

CM  1

CRN  1001017-91-9
CMF  C30 H40 N2 O

Absolute stereochemistry.  Rotation (-).




CM  2

CRN  144-62-7
CMF  C2 H2 O4



RN 1001017-94-2 CAPLUS
CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-[[(1R,2S)-2-(4-morpholinylmethyl)-2-phenylcyclopropyl]methyl]-, (2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-93-1
CMF C29 H38 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
GI




I




II

AB Disclosed are compds. according to formula I: wherein the variables are defined herein. Compds. of formula I wherein R is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, etc.; R1 is (un)substituted Ph, (un)substituted (mono/bi)cyclic heteroaryl and (un)substituted C3-7 cycloalkyl; X and Y are independently CH2 and a single bond; R2 is H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, etc.; A is (un)substituted (un)saturated (un)bridge 4- to 7-membered ring; Q and Y are attached to carbon or nitrogen in ring A via 1,2- or 1,3- or 1,4-relationship; Q is CO, CS, SO2, C=CH-NO2, C=N-CN, dioxocyclobutenylene, etc.; W is a bond and (un)substituted C1-5 alkylene; E is (un)substituted (un)saturated (un)bridge 3- to 7-membered ring; G is H, C1-6 alkyl, C4-7 heterocyclyl, OH, NH2 and derivs., etc.; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof, are claimed. Such compds. are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to formula I. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their renin inhibitory activity (some data given).

ACCESSION NUMBER: 2007:1177123 CAPLUS
DOCUMENT NUMBER: 147:469237
TITLE: Acylpiperidine compounds as renin inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with aspartic protease activity
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Cacatian, Salvacion; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mcgeehan, Gerard; Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.; Flaherty, Patrick T.; Kallander, Lara S.; Leach, Colin A.; Lawhorn, Brian; Lu, Qing; Terrell, Lamont R.; Ghavini-Alagha, Bahman; Zhang, Jing; Ghirlanda, Damiano; Hou, Xiaoping; Semus, Simon
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA; Smithkline Beecham Corporation
SOURCE: PCT Int. Appl., 619pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2007117482 | A2 | 20071018 | WO 2007-US8339 | 20070405 |
| WO 2007117482 | A3 | 20071122 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-789703P P 20060405
US 2006-789823P P 20060405

OTHER SOURCE(S): MARPAT 147:469237

IT 952706-35-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylpiperidine compds. as aspartic protease inhibitors including renin inhibitors useful in treatment of diseases - associated with aspartic protease activity)

RN 952706-35-3 CAPLUS

CN Methanone, [(3R)-3-[(1S)-1-(6-fluoro-3'-methyl[1,1'-biphenyl]-2-yl)-1-hydroxy-5-methoxypentyl]-1-piperidinyl][(1R,2R)-2-methyl-2-[(methylamino)methyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
GI




I




II

AB Described are compds. of formula I, which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compds. described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. Compds. of formula I wherein R is C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C2-7 cycloalkenyl, etc.; R1 is Ph, (mono/bi)cyclic heteroaryl, benzo-1,3-dioxole, benzo-1,3-dioxin, etc.; X and Y are independently CH2 and a single bond; R2 is H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 alkylthio, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, etc.; A is (un)substituted (un)saturated (un)bridge 4- to 7-membered ring; Q and U are attached to carbon or nitrogen atoms in ring A in a 1,2 or 1,3 or 1,4 relationship; Q is CO, CS, SO2, C=C-NO2, C=N-CN, dioxocyclobuteylene, etc.; E is (un)substituted (un)saturated (un)bridge 3- to 7-membered ring; G is OH, C1-6 hydroxyalkyl, amino, C1-6 aminoalkyl, C(=NH)NH2 and derivs., etc.; and their enantiomers, diastereoisomers and salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their renin inhibitory activity.

ACCESSION NUMBER: 2007:1177122 CAPLUS
DOCUMENT NUMBER: 147:469236
TITLE: Piperidinyl pyrrolidinyl methanone compounds as renin inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with aspartic protease activity
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Cacatian, Salvacion; Dillar, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mcgeehan, Gerard; Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 328pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2007117559 | A2 | 20071018 | WO 2007-US8520 | 20070405 |
| WO 2007117559 | A3 | 20071129 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,

GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-789703P P 20060405
US 2006-789823P P 20060405

OTHER SOURCE(S): MARPAT 147:469236

IT 952706-35-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolidinyl piperidinyl methanone compds. as aspartic protease inhibitors including renin inhibitors useful in treatment of diseases - associated with aspartic protease activity)

RN 952706-35-3 CAPLUS

CN Methanone, [(3R)-3-[(1S)-1-(6-fluoro-3'-methyl[1,1'-biphenyl]-2-yl)-1-hydroxy-5-methoxypentyl]-1-piperidinyl][(1R,2R)-2-methyl-2-[(methylamino)methyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB The aim of the present study was to investigate the biol. profile of new substituted 1-phenyl-2-cyclopropylmethylamines. High affinity for both σ subtypes was achieved when 4-phenylpiperidin-4-ol (4a-e) and 4-benzylpiperidine moieties were present (5a-e). (1R,2S/1S,2R)-2-[4-Hydroxy-(4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropanecarboxylate (4b) showed high affinity for the σ1 sites (Ki = 1.5 nM) and the most favorable σ1/σ2 selectivity (Ki(σ2)/Ki(σ1) = 33.9). Binding affinity studies showed that 4b binding on N-methyl-D-aspartate (NMDA), dopaminergic (D1, D2, D3), muscarinic, histaminergic H1, adrenergic (α1, α2), serotoninergic (5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT6), DA (DAT), and 5-HT (SERT) transporters was not significant. Interestingly, σ ligands differently induced the expression of tissue transglutaminase (TG-2) in primary astroglial cell cultures. We suggest that 4b may act as a σ1/σ2 agonist and that the σ ligands may modulate TG-2 differently.

ACCESSION NUMBER: 2007:160316 CAPLUS

DOCUMENT NUMBER: 146:394316

TITLE: Novel Sigma Receptor Ligands: Synthesis and Biological

Profile

AUTHOR(S): Prezzavento, Orazio; Campisi, Agata; Ronsisvalle, Simone; Li Volti, Giovanni; Marrazzo, Agostino; Bramanti, Vincenzo; Cannavo, Giuseppe; Vanella, Luca; Cagnotto, Alfredo; Mennini, Tiziana; Ientile, Riccardo; Ronsisvalle, Giuseppe

CORPORATE SOURCE: Department of Pharmaceutical Sciences and Department of Biological Chemistry Medical Chemistry and Molecular Biology, University of Catania, Catania, 95125, Italy

SOURCE: Journal of Medicinal Chemistry (2007), 50(5), 951-961
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:394316

IT 932737-00-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Novel Sigma Receptor Ligands: Synthesis and Biol. Profile)

RN 932737-00-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-(4-methylphenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 932736-89-5P 932736-91-9P 932736-94-2P
932736-95-3P 932736-97-5P 932736-99-7P
932737-01-4P 932737-03-6P 932737-05-8P
932737-07-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Novel Sigma Receptor Ligands: Synthesis and Biol. Profile)

RN 932736-89-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-phenyl-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-88-4
CMF C23 H27 N O3

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932736-91-9 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-(4-methylphenyl)-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-90-8
CMF C24 H29 N O3

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932736-94-2 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-(4-methoxyphenyl)-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-93-1
CMF C24 H29 N O4

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932736-95-3 CAPLUS
CN Cyclopropanecarboxylic acid, 1-(4-chlorophenyl)-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, methyl ester, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 932736-97-5 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-(4-nitrophenyl)-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-96-4
CMF C23 H26 N2 O5

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932736-99-7 CAPLUS
CN Cyclopropanecarboxylic acid, 1-phenyl-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (5:4) (CA INDEX NAME)

CM 1

CRN 932736-98-6
CMF C24 H29 N O2

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932737-01-4 CAPLUS
CN Cyclopropanecarboxylic acid, 1-(4-methylphenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (4:5) (CA INDEX NAME)

CM 1

CRN 932737-00-3
CMF C25 H31 N O2

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932737-03-6 CAPLUS
CN Cyclopropanecarboxylic acid, 1-(4-methoxyphenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932737-02-5
CMF C25 H31 N O3

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 932737-05-8 CAPLUS
CN Cyclopropanecarboxylic acid, 1-(4-chlorophenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932737-04-7
CMF C24 H28 Cl N O2

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 932737-07-0 CAPLUS
CN Cyclopropanecarboxylic acid, 1-(4-nitrophenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932737-06-9
CMF C24 H28 N2 O4

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

AB The title compds. (I) or salts thereof, and solvates of any of them [m, n, p = an integer of 0-2; q = 0, 1; R1 = halo, each (un)substituted hydrocarbyl, heterocyclyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, NH2, HO, CO2H, CONH2, or SO2NH2, C1-6 alkanoyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, NO2; R2 = halo, (un)substituted NH2, hydrocarbyl, or aromatic heterocyclyl, oxo; or two geminal or vicinal R2s together form C2-6 alkylene; R2 and the carbon atom attached to R2 together form a cyclic ring; X1 = O, (un)substituted NH, S, SO, SO2; X2 = CH2, O, (un)substituted NH, S, SO, SO2; Q1 = each (un)substituted heteroaryl, heteroarylalkyl, aryl, or aralkyl; the Cy ring = 5- or 6-membered aryl or heteroaryl; a dotted line represents the condensation of two rings; a wavy line represent E or Z configuration; some exceptions are defined] are prepared These compds. are useful for the treatment or prevention of pains. Thus, tri-Et phosphonoacetate was treated with NaH in THF at ≤20° for 1 h and condensed with 4-chromanone at room temperature overnight to give (E)-(chroman-4-ylidene)acetic acid Et ester which was refluxed in aqueous THF solution containing LiOH and neutralized with 1 N aqueous HCl solution to give (E)-(chroman-4-ylidene)acetic acid (II). II was condensed with 1,4-benzodioxan-6-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 at room temperature overnight to give (E)-2-(chroman-4-ylidene)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetamide (III). III and (E)-2-(8-trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene)-N-(quinoxalin-6-yl)acetamide in vitro showed A2 of ≥100 nM and <100 nM, resp., for antagonizing the capsaicin-induced cellular influx of Ca in CHO cell expressing human TRPV1. Pharmaceutical formulations, e.g. a tablet containing (E)-2-(7-tert-Butylchroman-4-ylidene)-N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide, were prepared

ACCESSION NUMBER: 2007:88232 CAPLUS
DOCUMENT NUMBER: 146:163039
TITLE: Preparation of novel 2-(bicyclic heterocyclidene)acetamide derivatives as antagonists of transient receptor potential type 1 (TRPV1)
INVENTOR(S): Uchida, Hideharu; Kosuga, Naoto; Satoh, Tsutomu; Hotta, Daido; Kamino, Tomoyuki; Maeda, Yoshitaka; Amano, Ken-Ichi; Akada, Yasushige

PATENT ASSIGNEE(S): Mochida Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 237pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2007010383 | A1 | 20070125 | WO 2006-IB2016 | 20060724 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006271297 | A1 | 20070125 | AU 2006-271297 | 20060724 |
| CA 2616079 | A1 | 20070125 | CA 2006-2616079 | 20060724 |
| EP 1908753 | A1 | 20080409 | EP 2006-779892 | 20060724 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| IN 2008DN00551 | A | 20080711 | IN 2008-DN551 | 20080121 |
| MX 200801048 | A | 20080502 | MX 2008-1048 | 20080122 |
| CN 101228131 | A | 20080723 | CN 2006-80026802 | 20080122 |
| KR 2008031971 | A | 20080411 | KR 2008-704378 | 20080222 |
| PRIORITY APPLN. INFO.: | | | JP 2005-213534 A | 20050722 |
| | | | JP 2005-330890 A | 20051115 |
| | | | JP 2006-45985 A | 20060222 |
| | | | WO 2006-IB2016 W | 20060724 |

OTHER SOURCE(S): MARPAT 146:163039

IT 920332-65-6P, (E)-2-[7-Trifluoromethyl-2,3-dihydro-1-[(2,2-dimethylcyclopropyl)carbonyl]quinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 2-(bicyclic heterocyclidene)acetamide derivs. as antagonists of transient receptor potential type 1 (TRPV1) for treatment or prevention of pains)

RN 920332-65-6 CAPLUS

CN Acetamide, 2-[1-[(2,2-dimethylcyclopropyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB Two efficient, simple, cheap, and environmentally benign prepns. of cyclopropanes were achieved. One was the formation via 3-exo-trig manner from various electron-deficient 2-iodoethyl-substituted olefins with zinc powder in a mixture of t-Bu alc. and water, and the other was the formation via 3-exo-tet manner from various 1,3-dihalopropanes with zinc powder in ethanol.

ACCESSION NUMBER: 2005:1008949 CAPLUS
DOCUMENT NUMBER: 143:459781
TITLE: Facile preparation of cyclopropanes from 2-iodoethyl-substituted olefins and 1,3-dihalopropanes with zinc powder
AUTHOR(S): Sakuma, Daisuke; Togo, Hideo
CORPORATE SOURCE: Graduate School of Science and Technology, Chiba University, Yayoi-cho 1-33, Inage-ku, Chiba, 263-8522, Japan
SOURCE: Tetrahedron (2005), 61(42), 10138-10145
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:459781
IT 827574-06-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cyclopropanes via zinc-mediated cyclopropanation of haloethyl-substituted olefins, iodomethylcyclohexanecarboxaldehyde, or dihalopropanes)
RN 827574-06-1 CAPLUS
CN Ethanone, 2-(2,2-dimethylcyclopropyl)-1-(1-piperidinyl)- (CA INDEX NAME)




REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

Q1= Q2= Q3=



AB The present invention relates to cyclopropyl derivs. of formula (I) or salts thereof such as pharmaceutically acceptable salts [wherein R1-R5 = independently H, halogen, cyano, nitro, C1-6 alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8 cycloalk(en)yl-C1-6-alk(en/yn)yl, amino, C1-6 alk(en/yn)ylamino, di[C1-6-alk(en/yn)yl]amino, C1-6 alk(en/yn)ylcarbonyl, aminocarbonyl, C1-6-alk(en/yn)ylaminocarbonyl, di[C1-6 alk(en)yl]aminocarbonyl, hydroxy, C1-6 alk(en/yn)yloxy, C1-6-alk(en/yn)ylthio, halo-C1-6 alk(en/yn)yl, halo-C1-6 alk(en/yn)ylsulfonyl, halo-C1-6 alk(en/yn)ylsulfanyl, and C1-6 alk(en/yn)ylsulfonyl; R6 = H, halo-C1-6 alk(en/yn)yl, C1-6 alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8 cycloalk(en)yl-C1-6 alk(en/yn)yl; R7 = aryl, heteroaryl, aryl-CR8R9- (wherein R8, R9 = H, C1-6 alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8 cycloalk(en)yl-C1-6 alk(en/yn)yl); n = 0-2; Q = Q1, Q2, Q3, etc.; R10, R12 = aryl; R11 = aryl, benzyl, halo-C1-6 alk(en/yn)ylsulfonyl, C1-6 alk(en/yn)ylsulfonyl, arylsulfonyl, arylacyl, C1-6-alk(en/yn)ylcarbonyl, aminocarbonyl, etc.; R13 = H, HO, cyano, or NH2, etc.]. These compds. are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, including psychotic disorders, schizophrenia, depression, anxiety, Parkinson's disease, pain, convulsions, cough, asthma, airway hyperresponsiveness, microvascular hypersensitivity, bronchoconstriction, gut inflammation, inflammatory bowel disease, hypertension, imbalances in water and electrolyte homeostasis, ischemia, edema, plasma extravasation, and obesity. For example, (1S,2R)-2-(4-acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide had an apparent NK3 affinity (Ki) of less than 50 nM in using a membrane prepared from baby hamster cells stably expressing the human NK3 receptor.

ACCESSION NUMBER: 2005:158639 CAPLUS
DOCUMENT NUMBER: 142:261403
TITLE: Preparation of 1-phenylcyclopropane-1-carboxamide derivatives as tachykinin NK3 receptor antagonists
INVENTOR(S): Kehler, Jan; Hansen, Tore; Poulsen, Anders; Bjornholm, Berith; Ruhland, Thomas; Norgaard, Morten Bang; Nielsen, Soren Moller
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005016884 | A1 | 20050224 | WO 2004-DK538 | 20040813 |
| WO 2005016884 | A9 | 20060316 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004265020 | A1 | 20050224 | AU 2004-265020 | 20040813 |
| CA 2535646 | A1 | 20050224 | CA 2004-2535646 | 20040813 |
| EP 1656349 | A1 | 20060517 | EP 2004-739035 | 20040813 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR 2004013584 | A | 20061017 | BR 2004-13584 | 20040813 |
| CN 1867549 | A | 20061122 | CN 2004-80029691 | 20040813 |
| JP 2007502253 | T | 20070208 | JP 2006-522897 | 20040813 |
| MX 2006PA01738 | A | 20060512 | MX 2006-PA1738 | 20060214 |
| IN 2006CN00544 | A | 20070622 | IN 2006-CN544 | 20060214 |
| NO 2006001137 | A | 20060309 | NO 2006-1137 | 20060309 |
| US 20060281746 | A1 | 20061214 | US 2006-568483 | 20060814 |
| PRIORITY APPLN. INFO.: | | | DK 2003-1175 A | 20030815 |
| | | | US 2003-501535P P | 20030908 |
| | | | WO 2004-DK538 W | 20040813 |

OTHER SOURCE(S): CASREACT 142:261403; MARPAT 142:261403

IT 846060-64-8P 846060-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 1-phenylcyclopropane-1-carboxamide derivs. as tachykinin NK3 receptor antagonists)

RN 846060-64-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-, methyl ester, (1S,2R)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 846060-63-7
CMF C25 H28 Cl2 N2 O3

Absolute stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 846060-65-9 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-, hydrochloride (1:1), (1S,2R)-
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 846060-75-1P, (1S,2S)-2-[(E)-3-(4-Acetylamino-4-phenylpiperidin-1-yl)-1-propenyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1-phenylcyclopropane-1-carboxamide derivs. as tachykinin NK3 receptor antagonists)
RN 846060-75-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1E)-3-[4-(acetylamino)-4-phenyl-1-piperidinyl]-1-propen-1-yl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 846059-18-5P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-19-6P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-20-9P 846059-21-0P 846059-22-1P 846059-23-2P 846059-24-3P, (1S,2R)-1-Phenyl-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-25-4P 846059-26-5P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-27-6P, (1S,2R)-2-[[4-(4-Chloro-3-trifluoromethylphenyl)-4-hydroxypiperidin-1-yl]methyl]-1-phenylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-28-7P 846059-29-8P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-30-1P, (1S,2R)-1-(4-Chlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-31-2P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-32-3P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-33-4P 846059-34-5P 846059-35-6P 846059-36-7P 846059-37-8P 846059-38-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-39-0P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-41-4P 846059-43-6P, (1S,2R)-2-[4-(4-Chloro-3-trifluoromethylphenyl)-4-hydroxypiperidin-1-ylmethyl]-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-44-7P 846059-45-8P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-48-1P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-50-5P 846059-52-7P 846059-54-9P, (1S,2R)-1-(4-Fluorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-56-1P 846059-58-3P, (1S,2R)-1-(3,4-Difluorophenyl)-2-[[4-phenyl-4-

[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid methylamide 846059-61-8P 846059-62-9P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-63-0P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-64-1P 846059-65-2P 846059-66-3P 846059-67-4P 846059-68-5P, (1S,2R)-1-Phenyl-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-69-6P, (1S,2R)-1-(4-Chlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-70-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-71-0P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-72-1P, (1S,2R)-1-(4-Chlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-73-2P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-74-3P 846059-75-4P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-76-5P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(3,4-difluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-77-6P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-78-7P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-79-8P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-80-1P 846059-81-2P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[(4-phenylpiperidin-1-yl)methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-82-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid (1-methyl-1-phenylethyl)amide 846059-83-4P, (1S,2R)-2-(4-Phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-ethylamide 846059-84-5P, (1R,2S)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-85-6P, (1R,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-86-7P, (1S,2S)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-87-8P 846059-88-9P 846059-89-0P 846059-90-3P 846059-91-4P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-92-5P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-93-6P 846059-94-7P, (1S,2R)-2-[[4-[(Acetyl)(methyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide

846059-95-8P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-96-9P 846059-97-0P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(3,4-difluorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-98-1P 846059-99-2P 846060-00-2P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-01-3P 846060-02-4P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-03-5P, (1S,2R)-1-(4-Fluorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-04-6P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-difluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-06-8P, (1S,2R)-1-(3,4-Difluorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-07-9P 846060-08-0P 846060-09-1P 846060-10-4P 846060-11-5P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid phenylamide 846060-19-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid benzylamide 846060-20-6P 846060-21-7P 846060-22-8P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)amide 846060-23-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(3,4-dichlorobenzyl)amide 846060-24-0P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-methyl-N-phenylamide 846060-25-1P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-methoxyphenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-26-2P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-p-tolylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-27-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-m-tolylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-28-4P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-m-tolylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-29-5P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3-methoxyphenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-30-8P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-methoxyphenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-31-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-p-tolylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-32-0P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3-methoxyphenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-33-1P, (1S,2R)-1-Phenyl-2-(4-phenyl-4-ureidopiperidin-1-ylmethyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-34-2P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[(4-phenyl-4-ureidopiperidin-1-yl)methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-35-3P, (1S,2R)-1-Phenyl-2-[4-(N'-methylureido)-4-phenylpiperidin-1-ylmethyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-36-4P, (1S,2R)-2-[4-(N'-Methylureido)-4-phenylpiperidin-1-

ylmethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-37-5P, N-[1-[[(1S,2R)-2-[(4-Fluorobenzyl)(methyl)carbamoyl]-2-phenylcyclopropyl]methyl]-4-phenylpiperidin-4-yl]oxalamide 846060-38-6P, N-[1-[[(1S,2R)-2-(N-Benzyl-N-methylcarbamoyl)-2-(3,4-dichlorophenyl)cyclopropyl]methyl]-4-phenylpiperidin-4-yl]oxalamide 846060-39-7P, (1S,2R)-1-Phenyl-2-[[4-[(methylsulfonyl)amino]-4-phenylpiperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-40-0P, (1S,2R)-2-[[4-[(Methylsulfonyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-41-1P, [1-[[(1S,2R)-2-[N-(4-Fluorobenzyl)-N-methylcarbamoyl]-2-phenylcyclopropyl]methyl]-4-phenylpiperidin-4-yl]carbamic acid methyl ester 846060-42-2P, [1-[[(1S,2R)-2-(N-Benzyl-N-methylcarbamoyl)-2-(3,4-dichlorophenyl)cyclopropyl]methyl]-4-phenylpiperidin-4-yl]carbamic acid methyl ester 846060-43-3P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-(N',N'-dimethylureido)-4-phenylpiperidin-1-yl]methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-44-4P, (1S,2R)-1-Phenyl-2-[4-(N',N'-dimethylureido)-4-phenylpiperidin-1-ylmethyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-45-5P, (1S,2R)-2-[2-(4-Acetylamino-4-phenylpiperidin-1-yl)ethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-46-6P, (1S,2R)-2-[3-(4-Acetylamino-4-phenylpiperidin-1-yl)propyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-47-7P, (1S,2R)-2-[4-(2-Acetylamino-5-fluorophenyl)piperidin-1-ylmethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-48-8P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dimethylphenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-49-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-50-2P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-51-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3-fluorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846060-52-4P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[(4-phenylpiperidin-1-yl)methyl]cyclopropanecarboxylic acid N-methyl-N-(naphthalen-1-ylmethyl)amide 846060-53-5P 846060-54-6P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[(4-Acetylamino-4-phenylpiperidin-1-yl)methyl]cyclopropanecarboxylic acid N-methyl-N-(naphthalen-1-ylmethyl)amide 846060-76-2P, (1S,2S)-2-[2-(4-Acetylamino-4-phenylpiperidin-1-yl)ethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-phenylcyclopropane-1-carboxamide derivs. as tachykinin NK3 receptor antagonists)

RN 846059-18-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-19-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-20-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-21-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-22-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-23-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 846059-24-3 CAPLUS
CN Cyclopropanecarboxamide, N-methyl-1-phenyl-N-(phenylmethyl)-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-25-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-26-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-27-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-28-7 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-29-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-30-1 CAPLUS
CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-31-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-32-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-33-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-34-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-35-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-difluorophenyl)-N-methyl-N-(1-phenylethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 846059-36-7 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-difluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 846059-37-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 846059-38-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-39-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-41-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-43-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-44-7 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-45-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-48-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-50-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-

methyl-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-52-7  CAPLUS
CN  Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-54-9  CAPLUS
CN  Cyclopropanecarboxamide, 1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-56-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-58-3 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-difluorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-61-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-[(4-

fluorophenyl)methyl]-N-methyl-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-62-9  CAPLUS
CN  Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-63-0  CAPLUS
CN  Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-64-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-fluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-65-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(1-phenylethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-66-3 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-67-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-68-5 CAPLUS
CN Cyclopropanecarboxamide, N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-69-6 CAPLUS
CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-70-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-

, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-71-0  CAPLUS
CN  Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-72-1  CAPLUS
CN  Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN  846059-73-2  CAPLUS
CN  Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)-  (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-74-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-75-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(4-fluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-76-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-77-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-78-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-79-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-80-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-81-2 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-2-[(4-phenyl-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-82-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-(1-methyl-1-phenylethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-83-4 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-ethyl-N-(phenylmethyl)-2-[(4-phenyl-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-84-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-85-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-86-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-87-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-88-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-89-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-90-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 846059-91-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-92-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-93-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-94-7 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-95-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX

NAME)

Absolute stereochemistry.




RN 846059-96-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-97-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(3,4-difluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-98-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-99-2 CAPLUS
CN Cyclopropanecarboxamide, 1-(4-fluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-00-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-01-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-02-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(4-fluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-03-5 CAPLUS
CN Cyclopropanecarboxamide, N-[(2-chlorophenyl)methyl]-1-(4-fluorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-04-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-06-8 CAPLUS
CN Cyclopropanecarboxamide, N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-07-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-08-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-09-1 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-[(3,4-dichlorophenyl)methyl]-2-[(4-phenyl-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-10-4 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-[(3,4-dimethoxyphenyl)methyl]-2-[(4-phenyl-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-11-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-19-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-20-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-[(2-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-21-7 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[1-(4-methoxyphenyl)ethyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-22-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-23-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[(3,4-dichlorophenyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-24-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-25-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-1-(4-methoxyphenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-26-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-

piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-(4-methylphenyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-27-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-methyl-1-(3-methylphenyl)-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-28-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-(3-methylphenyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-29-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-1-(3-methoxyphenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-30-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-methoxyphenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-31-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-methyl-1-(4-methylphenyl)-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-32-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3-methoxyphenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-33-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-[(aminocarbonyl)amino]-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-34-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-[(aminocarbonyl)amino]-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-35-3 CAPLUS
CN Cyclopropanecarboxamide, N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-[[(methylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]methyl]-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-36-4 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-2-[[4-[[(methylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]methyl]-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-37-5 CAPLUS
CN Ethanediamide, N1-[1-[[(1S,2R)-2-[[[(4-fluorophenyl)methyl]methylamino]carbonyl]-2-phenylcyclopropyl]methyl]-4-phenyl-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-38-6 CAPLUS
CN Ethanediamide, N1-[1-[[(1S,2R)-2-(3,4-dichlorophenyl)-2-[[methyl(phenylmethyl)amino]carbonyl]cyclopropyl]methyl]-4-phenyl-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-39-7 CAPLUS
CN Cyclopropanecarboxamide, N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-[(methylsulfonyl)amino]-4-phenyl-1-piperidinyl]methyl]-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-40-0 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-2-[[4-[(methylsulfonyl)amino]-4-phenyl-1-piperidinyl]methyl]-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-41-1 CAPLUS
CN Carbamic acid, [1-[[(1S,2R)-2-[[[(4-fluorophenyl)methyl]methylamino]carbonyl]-2-phenylcyclopropyl]methyl]-4-phenyl-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-42-2 CAPLUS
CN Carbamic acid, [1-[[(1S,2R)-2-(3,4-dichlorophenyl)-2-[[methyl(phenylmethyl)amino]carbonyl]cyclopropyl]methyl]-4-phenyl-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-43-3 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-2-[[4-[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]methyl]-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-44-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-45-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[2-[4-(acetylamino)-4-phenyl-1-piperidinyl]ethyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-46-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[3-[4-(acetylamino)-4-phenyl-1-piperidinyl]propyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-47-7 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-[2-(acetylamino)-5-fluorophenyl]-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-48-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dimethylphenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-49-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-50-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-51-3 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-52-4 CAPLUS
CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-(1-naphthalenylmethyl)-2-[(4-phenyl-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-53-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(1-naphthalenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-54-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(1-naphthalenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-76-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[2-[4-(acetylamino)-4-phenyl-1-piperidinyl]ethyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB An efficient, simple cheap, and environmentally benign preparation of cyclopropanes by 3-exo-trig manner from various electron-deficient 2-iodoethyl-substituted olefins with zinc powder in a mixture of t-Bu alc. and water was achieved.

ACCESSION NUMBER: 2004:1062615 CAPLUS
DOCUMENT NUMBER: 142:155563
TITLE: Facile and environmentally benign Zn-mediated cyclopropanation of electron-deficient 2-iodoethyl-substituted olefins via radical 3-exo-trig manner
AUTHOR(S): Sakuma, Daisuke; Togo, Hideo
CORPORATE SOURCE: Graduate School of Science and Technology, Chiba University, Chiba, 263-8522, Japan
SOURCE: Synlett (2004), (14), 2501-2504
CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:155563
IT 827574-06-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cyclopropanes via zinc-mediated radical cyclopropanation of alkenyl halides)
RN 827574-06-1 CAPLUS
CN Ethanone, 2-(2,2-dimethylcyclopropyl)-1-(1-piperidinyl)- (CA INDEX NAME)




REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=>
=>
=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 18:51:56 ON 17 NOV 2008